Arix Bioscience (LON:ARIX) Hits New 12-Month Low at $130.00
Arix Bioscience PLC (LON:ARIX)’s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 130 ($1.70) and last traded at GBX 131 ($1.71), with a volume of 19190 shares changing hands. The stock had previously closed at GBX 131 ($1.71).
ARIX has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price target on Estee Lauder Companies from $157.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Jefferies Financial Group decreased their price target on MAV Beauty Brands from C$15.00 to C$14.00 in a report on Friday, March 29th.
The company has a market capitalization of $177.57 million and a P/E ratio of 4.56. The stock’s fifty day moving average is GBX 138.65.
Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, medical innovation comprising healthcare and life sciences.
Featured Story: Trading on Margin
Receive News & Ratings for Arix Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arix Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.